Tirzepatide and Zepbound: the US brand name, the UK reality

What SURMOUNT-1 and SURMOUNT-5 found about tirzepatide

The strongest evidence for tirzepatide in weight management comes from the SURMOUNT clinical programme. SURMOUNT-1 randomised 2,539 adults with obesity but without type 2 diabetes; at 72 weeks, participants on the 15 mg dose lost an average of around 20–21% of their body weight, a finding that shaped the MHRA's decision to license Mounjaro and NICE's appraisal of tirzepatide (TA1026), published in December 2024. More recently, the SURMOUNT-5 head-to-head trial compared tirzepatide directly with semaglutide 2.4 mg in adults with obesity and reported that tirzepatide produced a greater average reduction over 72 weeks, the first direct comparison of its kind published in the New England Journal of Medicine. These figures are from controlled trial conditions with lifestyle support, so individual results in real-world practice vary. The data nonetheless moved tirzepatide to the front of the clinical conversation about weight-loss treatment options in the UK.

Zepbound versus Mounjaro: same molecule, different markets

The distinction between Zepbound and Mounjaro is purely one of geography and branding. Eli Lilly markets tirzepatide as Zepbound in the United States for weight management and as Mounjaro in the UK and Europe for both weight management and type 2 diabetes. The active ingredient, the mechanism, and the clinical data behind them are the same. US dosing presentations, US pricing, and US insurance context have no relevance to UK patients, and the Zepbound name carries no UK marketing authorisation from the MHRA. Anyone offering Zepbound-branded product to a UK buyer would be operating outside the licensed UK supply chain. For a deeper comparison of how the two brand names relate in practice, this page on whether Zepbound and Mounjaro are the same medicine covers the specifics.

If you are researching whether there is also an oral form of tirzepatide, the picture on oral tirzepatide and Zepbound is more nuanced, worth reading before drawing conclusions.

What is actually licensed for weight management in the UK

Two medicines hold a UK marketing authorisation for weight management in adults: tirzepatide (Mounjaro) and semaglutide (Wegovy). NICE recommends tirzepatide under TA1026 for adults with a BMI of 35 or above plus at least one weight-related condition, with lower BMI thresholds applying for some ethnic backgrounds under UK guidance. Wegovy carries its own NICE recommendation under TA875. Neither Zepbound nor any US-branded version of tirzepatide sits within this framework. The NHS is also rolling out tirzepatide in primary care under a phased eligibility programme, though waiting lists and local criteria vary significantly. For patients who do not meet NHS thresholds or prefer not to wait, a private prescription through a GPhC-registered pharmacy like ours is the regulated alternative, subject to a full clinical assessment. You can read more about the licensed use of tirzepatide in the UK and understand what the consultation process involves.

Safety, side effects, and what to watch for

Because Zepbound and Mounjaro are the same molecule, the safety profile is identical. The most commonly reported side effects are gastrointestinal: nausea, loose stools, constipation, and indigestion tend to be most noticeable in the early weeks or after a dose step, and generally ease as the body adjusts. The NHS tirzepatide medicines page lists the full side-effect profile and explains which symptoms need prompt medical attention. The MHRA has also flagged acute pancreatitis as a known, though uncommon, risk with GLP-1 medicines: severe stomach pain that spreads toward the back warrants urgent medical review. Tirzepatide holds a Black Triangle (▼) status in the UK, meaning additional post-market monitoring is ongoing. Anyone researching what happens to weight after stopping tirzepatide will find that a separate page covers that question directly. If Mounjaro is the medicine you want to understand in full detail, the Mounjaro treatment overview sets out eligibility, how the prescription process works, and what arrives, a tracked DPD parcel in plain, unbranded packaging, with the KwikPen inside ready to refrigerate.